Christopher J Graber1, Makoto M Jones2, Peter A Glassman1, Charlene Weir3, Jorie Butler4, Kevin Nechodom3, Chad L Kay5, Amy E Furman5, Thuong T Tran6, Christopher Foltz6, Lori A Pollack7, Matthew H Samore3, Matthew Bidwell Goetz1. 1. VA Greater Los Angeles Healthcare System, Los Angeles, California; David Geffen School of Medicine at the University of California, Los Angeles. 2. IDEAS Center, VA Salt Lake City Healthcare System, Salt Lake City, Utah; Geriatric Research and Clinical Education Center, VA Salt Lake City Healthcare System, Salt Lake City, Utah. 3. IDEAS Center, VA Salt Lake City Healthcare System, Salt Lake City, Utah; University of Utah, Salt Lake City. 4. IDEAS Center, VA Salt Lake City Healthcare System, Salt Lake City, Utah; Geriatric Research and Clinical Education Center, VA Salt Lake City Healthcare System, Salt Lake City, Utah; University of Utah, Salt Lake City. 5. VA Sierra Nevada Healthcare System , Palo Alto, California, and Reno, Nevada. 6. VA Greater Los Angeles Healthcare System , Los Angeles, California. 7. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention , Atlanta, Georgia .
Abstract
BACKGROUND: Antibiotic time-outs can promote critical thinking and greater attention to reviewing indications for continuation. OBJECTIVE: We pilot tested an antibiotic time-out program at a tertiary care teaching hospital where vancomycin and piperacillin-tazobactam continuation past day 3 had previously required infectious diseases service approval. METHODS: The time-out program consisted of 3 components: (1) an electronic antimicrobial dashboard that aggregated infection-relevant clinical data; (2) a templated note in the electronic medical record that included a structured review of antibiotic indications and that provided automatic approval of continuation of therapy when indicated; and (3) an educational and social marketing campaign. RESULTS: In the first 6 months of program implementation, vancomycin was discontinued by day 5 in 93/145 (64%) courses where a time-out was performed on day 4 versus in 96/199 (48%) 1 year prior (P = .04). Seven vancomycin continuations via template (5% of time-outs) were guideline-discordant by retrospective chart review versus none 1 year prior (P = .002). Piperacillin-tazobactam was discontinued by day 5 in 70/105 (67%) courses versus 58/93 (62%) 1 year prior (P = .55); 9 continuations (9% of time-outs) were guideline-discordant versus two 1 year prior (P = .06). A usability survey completed by 32 physicians demonstrated modest satisfaction with the overall program, antimicrobial dashboard, and renewal templates. CONCLUSIONS: By providing practitioners with clinical informatics support and guidance, the intervention increased provider confidence in making decisions to de-escalate antimicrobial therapy in ambiguous circumstances wherein they previously sought authorization for continuation from an antimicrobial steward.
BACKGROUND: Antibiotic time-outs can promote critical thinking and greater attention to reviewing indications for continuation. OBJECTIVE: We pilot tested an antibiotic time-out program at a tertiary care teaching hospital where vancomycin and piperacillin-tazobactam continuation past day 3 had previously required infectious diseases service approval. METHODS: The time-out program consisted of 3 components: (1) an electronic antimicrobial dashboard that aggregated infection-relevant clinical data; (2) a templated note in the electronic medical record that included a structured review of antibiotic indications and that provided automatic approval of continuation of therapy when indicated; and (3) an educational and social marketing campaign. RESULTS: In the first 6 months of program implementation, vancomycin was discontinued by day 5 in 93/145 (64%) courses where a time-out was performed on day 4 versus in 96/199 (48%) 1 year prior (P = .04). Seven vancomycin continuations via template (5% of time-outs) were guideline-discordant by retrospective chart review versus none 1 year prior (P = .002). Piperacillin-tazobactam was discontinued by day 5 in 70/105 (67%) courses versus 58/93 (62%) 1 year prior (P = .55); 9 continuations (9% of time-outs) were guideline-discordant versus two 1 year prior (P = .06). A usability survey completed by 32 physicians demonstrated modest satisfaction with the overall program, antimicrobial dashboard, and renewal templates. CONCLUSIONS: By providing practitioners with clinical informatics support and guidance, the intervention increased provider confidence in making decisions to de-escalate antimicrobial therapy in ambiguous circumstances wherein they previously sought authorization for continuation from an antimicrobial steward.
Authors: Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton Journal: Clin Infect Dis Date: 2006-12-13 Impact factor: 9.079
Authors: Megan K Shaughnessy; William H Amundson; Michael A Kuskowski; Douglas D DeCarolis; James R Johnson; Dimitri M Drekonja Journal: Infect Control Hosp Epidemiol Date: 2012-12-19 Impact factor: 3.254
Authors: Harold C Standiford; Shannon Chan; Megan Tripoli; Elizabeth Weekes; Graeme N Forrest Journal: Infect Control Hosp Epidemiol Date: 2012-04 Impact factor: 3.254
Authors: Rebecca R Roberts; Bala Hota; Ibrar Ahmad; R Douglas Scott; Susan D Foster; Fauzia Abbasi; Shari Schabowski; Linda M Kampe; Ginevra G Ciavarella; Mark Supino; Jeremy Naples; Ralph Cordell; Stuart B Levy; Robert A Weinstein Journal: Clin Infect Dis Date: 2009-10-15 Impact factor: 9.079
Authors: E Charani; E Castro-Sanchez; N Sevdalis; Y Kyratsis; L Drumright; N Shah; A Holmes Journal: Clin Infect Dis Date: 2013-04-09 Impact factor: 9.079
Authors: K Chrysou; O Zarkotou; S Kalofolia; P Papagiannakopoulou; G Chrysos; K Themeli-Digalaki; A Tsakris; S Pournaras Journal: Eur J Clin Microbiol Infect Dis Date: 2017-11-19 Impact factor: 3.267
Authors: Christopher J Graber; Makoto M Jones; Matthew Bidwell Goetz; Karl Madaras-Kelly; Yue Zhang; Jorie M Butler; Charlene Weir; Ann F Chou; Sarah Y Youn; Matthew H Samore; Peter A Glassman Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Peter Taber; Charlene Weir; Jorie M Butler; Christopher J Graber; Makoto M Jones; Karl Madaras-Kelly; Yue Zhang; Ann F Chou; Matthew H Samore; Matthew Bidwell Goetz; Peter A Glassman Journal: Am J Infect Control Date: 2021-01-27 Impact factor: 2.918
Authors: Daniel L Giesler; Sarah Krein; Adamo Brancaccio; Daraoun Mashrah; David Ratz; Tejal Gandhi; Linda Bashaw; Jennifer Horowitz; Valerie Vaughn Journal: Am J Infect Control Date: 2021-11-28 Impact factor: 4.303